{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":50,"description":"apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months\n\nApixaban: apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months","id":"EG000","otherNumAffected":3,"otherNumAtRisk":50,"seriousNumAffected":0,"seriousNumAtRisk":50,"title":"Apixaban"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":50,"numEvents":3}],"term":"non-major bleeding"}],"timeFrame":"1 year"}